Quantum Biopharma Ltd (HUGE) Stock Analysis
Verdict: AVOID
Rapidly depleting cash reserves and zero revenue suggest a high probability of total capital loss before clinical milestones are reached.
Investment score: 12/100
Analysis as of
Is Quantum Biopharma Ltd stock worth reviewing? The TradeMates thesis
Quantum Biopharma is a distressed micro-cap pharmaceutical company with zero revenue, declining assets (from $62M in 2021 to $17M in 2023), and a current ratio (0.63) that signals technical insolvency risk.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Quantum Biopharma Ltd opportunities and risks
What speaks for HUGE
- Phase II Clinical Success
What speaks against HUGE
- Imminent Liquidity Rupture
Peers and competitors
- HEXO.TO
- ZYUS.V
- ALGO.NE
- LABS.TO
- QNTM.CN
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HUGE | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -17303.0% |
| HEXO.TO | n/a | 0.2x | n/a | -39.6% | -561.8% | -391.0% |
| LABS.TO | n/a | 0.7x | n/a | 30.6% | -20.2% | -10.4% |
| Peer median | n/a | 0.5x | n/a | -4.5% | -291.0% | -200.7% |
Frequently asked questions about Quantum Biopharma Ltd (HUGE)
Is HUGE stock a good investment?
The TradeMates model rates Quantum Biopharma Ltd as AVOID with an investment score of 12/100. Quantum Biopharma is a distressed micro-cap pharmaceutical company with zero revenue, declining assets (from $62M in 2021 to $17M in 2023), and a current ratio (0.63) that signals technical insolvency risk. This is algorithmic model output, not personal investment advice.
Is HUGE stock a buy?
The TradeMates model verdict for HUGE is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.